Predictive cancer diagnostics technology company Rhythm Biosciences (ASX:RHY) has created its Clinical Advisory Board (CAB).
The company said the CAB will provide guidance on scientific, clinical, and regulatory aspects for the ColoSTAT test’s further developmental process.
The ColoSTAT Test-Kit is Rhythm Bioscience’s blood-based test for detecting colorectal cancer (CRC). It measures five specific protein biomarkers that indicate the likelihood of CRC.
The company said CAB will advise on the data and outcome measures to ensure the ColoSTAT IVDR is ready for registration and launch in different international markets.
The CAB members are Dr Sally Benton (consultant clinical biochemist and clinical lead for clinical and specialist biochemistry services at Berkshire and Surrey pathology services), Professor Jon Emery (Herman Professor of Primary Care Cancer Research at the University of Melbourne, and the Victorian Comprehensive Cancer Centre Primary Care Research and Education Lead), and Professor Finlay Macrae (head of colorectal medicine and genetics at The Royal Melbourne Hospital).
“We are honoured to have world-class, distinguished leaders in their field of Colorectal Cancer diagnostics form our CAB and look forward to their expertise and guidance in this significant commercialisation stage of ColoSTAT,” said Otto Buttula, executive chairman of Rhythm.